Unknown

Dataset Information

0

CtDNA-adjusted bTMB as a predictive biomarker for patients with NSCLC treated with PD-(L)1 inhibitors.


ABSTRACT:

Background

In non-small cell lung cancer (NSCLC) patients receiving immune checkpoint inhibitors (ICIs), higher blood tumor mutational burden (bTMB) was usually associated with better progression-free survival (PFS) and objective response rate (ORR). However, the association between bTMB and overall survival (OS) benefit remains undefined. It has been reported that patients harboring a high level of circulating tumor DNA (ctDNA) had poor survival. We hypothesized that ctDNA-adjusted bTMB might predict OS benefit in NSCLC patients receiving ICIs.

Methods

Our study was retrospectively performed in three cohorts, including OAK and POPLAR cohort (n = 853), Shanghai and Wuhan (SH&WH) cohort (n = 44), and National Cancer Center (NCC) cohort (n = 47). Durable clinical benefit (DCB) was defined as PFS lasting ≥ 6 months. The cutoff value of ctDNA-adjusted bTMB for DCB prediction was calculated based on a receiver operating characteristic curve. Interaction between treatments and ctDNA-adjusted bTMB was assessed.

Results

The bTMB score was significantly associated with tumor burden, while no association was observed between ctDNA-adjusted bTMB with tumor burden. In the OAK and POPLAR cohort, significantly higher ORR (P = 0.020) and DCB (P < 0.001) were observed in patients with high ctDNA-adjusted bTMB than those with low ctDNA-adjusted bTMB. Importantly, the interactions between ctDNA-adjusted bTMB and treatments were significant for OS (interaction P = 0.019) and PFS (interaction P = 0.002). In the SH&WH cohort, the interactions between ctDNA-adjusted bTMB and treatment were marginally significant for OS (interaction P = 0.081) and PFS (interaction P = 0.062). Similar result was demonstrated in the NCC cohort.

Conclusions

Our study indicated that ctDNA-adjusted bTMB might predict OS benefit in NSCLC patients receiving ICIs. The potential of ctDNA-adjusted bTMB as a noninvasive predictor for immunotherapy should be confirmed in future studies.

SUBMITTER: Nie W 

PROVIDER: S-EPMC9069852 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

ctDNA-adjusted bTMB as a predictive biomarker for patients with NSCLC treated with PD-(L)1 inhibitors.

Nie Wei W   Wang Zhi-Jie ZJ   Zhang Kai K   Li Bing B   Cai Yi-Ran YR   Wen Feng-Cai FC   Zhang Ding D   Bai Yue-Zong YZ   Zhang Xue-Yan XY   Wang Shu-Yuan SY   Cheng Lei L   Zhong Hua H   Liu Li L   Wang Jie J   Han Bao-Hui BH  

BMC medicine 20220505 1


<h4>Background</h4>In non-small cell lung cancer (NSCLC) patients receiving immune checkpoint inhibitors (ICIs), higher blood tumor mutational burden (bTMB) was usually associated with better progression-free survival (PFS) and objective response rate (ORR). However, the association between bTMB and overall survival (OS) benefit remains undefined. It has been reported that patients harboring a high level of circulating tumor DNA (ctDNA) had poor survival. We hypothesized that ctDNA-adjusted bTMB  ...[more]

Similar Datasets

| S-EPMC11390629 | biostudies-literature
| S-EPMC9762332 | biostudies-literature
| S-EPMC5363800 | biostudies-literature
| S-EPMC10307873 | biostudies-literature
| S-EPMC11347672 | biostudies-literature
| S-EPMC10166972 | biostudies-literature
| S-EPMC10772261 | biostudies-literature
| S-EPMC7481592 | biostudies-literature
| S-EPMC5540774 | biostudies-literature
| S-EPMC8649001 | biostudies-literature